RVV:TSX.V

Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation
RVV:TSX.V

Expert Comments:

Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations.
read more >

All Penny Stocks

(5/14/20)
Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders. The company is exploring the use of Bucillamine for the potential treatment of COVID-19. . .with its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. . .the company's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases, with the company being granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and. . .ischemia and reperfusion injury from organ transplantation.


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Strong IP in infectious diseases, psilocybin, and cannabis
 
Phase 2 for use of Bucillamine to treat gout and moving to Phase
 
Undervalued next to peers
catalyst Calendar
Q3
2020
Q3
2020
Partnership with University of Wisconsin in clinical studies with psillocybin
Revive Therapeutics Ltd. Content